42 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
TEVA Teva Pharmaceutical Industries Limited $23.43 $23.86B N/A
Article Searches
Why Long-Term Investors Should Avoid TEVA Stock Like the Plague https://www.fool.com/investing/2020/01/22/why-long-term-investors-should-avoid-teva-stock-li.aspx?source=iedfolrf0000001 Jan 22, 2020 - Strapped with debt and battling legal controversies right and left, Teva’s best days could very well be behind it.
Why You Should Still Buy Teva https://seekingalpha.com/article/4318277-why-you-should-still-buy-teva?source=feed_tag_israel Jan 22, 2020 - Teva is set to hold the $10 support line.Company's restructuring and debt reduction on schedule.Future growth in place with two products leading it.
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258 http://www.zacks.com/stock/news/730536/jazz-jazz-submits-nda-for-xyrem-follow-on-candidate-jzp-258?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-730536 Jan 23, 2020 - Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.
Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258 (Revised) http://www.zacks.com/stock/news/736017/jazz-jazz-submits-nda-for-xyrem-follow-on-candidate-jzp-258-revised?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-736017 Jan 28, 2020 - Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.
The FDA and FTC Announce an Effort to Deter Anti-Competitive Practices Among Drugmakers https://www.fool.com/investing/2020/02/03/fda-and-ftc-announces-plans-to-deter-anti-competit.aspx?source=iedfolrf0000001 Feb 03, 2020 - Regulators are trying their best to help encourage competition, particularly in the biosimilars market.
Teva Pharmaceutical Industries Ltd. (TEVA) Gains But Lags Market: What You Should Know http://www.zacks.com/stock/news/751299/teva-pharmaceutical-industries-ltd-teva-gains-but-lags-market-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-751299 Feb 05, 2020 - Teva Pharmaceutical Industries Ltd. (TEVA) closed the most recent trading day at $12.10, moving +0.33% from the previous trading session.
Teva (TEVA) to Report Q4 Earnings: What's in the Cards? http://www.zacks.com/stock/news/754447/teva-teva-to-report-q4-earnings-whats-in-the-cards?cid=CS-ZC-FT-analyst_blog|earnings_preview-754447 Feb 07, 2020 - Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to have hurt Teva's (TEVA) Q4 sales.
Q4 Earnings Outlook For Teva http://feeds.benzinga.com/~r/benzinga/~3/SEU7X2jchh0/earnings-outlook-for-teva-pharmaceutical-indus Feb 11, 2020 -

Teva Pharmaceutical Indus (NYSE: TEVA) announces its next round of earnings this Wednesday, February 12. Here is Benzinga's everything-that-matters guide for the Q4 earnings announcement.

read more

TEVA, SHOP among premarket gainers https://seekingalpha.com/news/3541047-teva-shop-among-premarket-gainers?utm_source=feed_news_all&utm_medium=referral Feb 12, 2020 - AIM ImmunoTech (NYSEMKT:AIM) +20% on discussing the potential role of Ampligen for use against the Wuhan 2019 Novel Coronavirus.TransEnterix (NYSEMKT:TRXC) +19% on CE Mark for pediatric use of Senhanc
Teva Pharmaceutical Industries Limited (TEVA) Q4 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2020/02/12/teva-pharmaceutical-industries-limited-teva-q4-201.aspx?source=iedfolrf0000001 Feb 12, 2020 - TEVA earnings call for the period ending December 31, 2019.

Pages: 12345

<Page 2>